Plus, a quiet winner of the US defense budget, a COVID-era darling due for a resurgence, and a top-tier analyst’s contrarian call carrying more than 100% upside potential.
Mar 14, 2026
Apr 25, 2026
•
1 min read
Plus, the latest ticker from a Wall Street analyst with +186% average returns, a Top 1% analyst's take on Tesla, and more.
Apr 18, 2026
Plus, a Permian Basin play that just got a 73% PT bump, a GPCR drug developer with 60% upside potential, and more...
Apr 11, 2026
2 min read
Plus, a precision oncology biotech with room to run, a CNS drug challenger with nearly $4B in projected peak sales, and more...
